Loss of BAP1 expression occurs frequently in intrahepatic cholangiocarcinoma

Medicine (United States)

Volumn 95, Issue 2, 2016, Pages

  Andrici, Juliana ^a,e   Goeppert, Benjamin ^b   Sioson, Loretta ^a,c   Clarkson, Adele ^a   Renner, Marcus ^b   Stenzinger, Albrecht ^b   Tayao, Michael ^a   Watson, Nicole ^a   Farzin, Mahtab ^a,c   Toon, Christopher W ^a,d,e   Smith, Ross C ^e   Mittal, Anubhav ^c,e,f   Samra, Jaswinder S ^c,e,f,g   Hugh, Thomas J ^c,e,f   Chou, Angela ^c,h   Lawlor, Rita T ⁱ   Weichert, Wilko ^b   Schirmacher, Peter ^b   Sperandio, Nicola ⁱ   Ruzzenente, Andrea ^j   Scarpa, Aldo ⁱ   Gill, Anthony J ^a,c,e   more..

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d Histopath Pathology   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

^g MACQUARIE UNIVERSITY HOSPITAL   (Australia)

^h ST VINCENT S HOSPITAL   (Australia)

ⁱ ARC net   (Italy)

^j UNIVERSITY AND HOSPITAL TRUST OF VERONA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BAP1 PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN THIOLESTERASE;

ADULT; AGED; BILE DUCT CARCINOMA; BILE DUCT TUMOR; CLINICAL TRIAL; EPIDEMIOLOGY; FEMALE; GERMANY; HUMAN; INTRAHEPATIC BILE DUCT; ITALY; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEW SOUTH WALES; PATHOLOGY; PHENOTYPE; RETROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BIOMARKERS, TUMOR; CHOLANGIOCARCINOMA; FEMALE; GERMANY; HUMANS; ITALY; MALE; MIDDLE AGED; NEW SOUTH WALES; PHENOTYPE; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE;

EID: 84958212007     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000002491     Document Type: Article

References (31)

1. Murali R, Wiesner T, Scolyer RA. Tumors associated with BAP1 mutation. Pathol. 2013;45:116-126.
2. Battaglia A. The importance of multidisciplinary approach in early detection of BAP1 tumor predisposition syndrome: clinical management and risk assessment. Clin Med Insights Oncol. 2014;8:37-47.
3. Jiao Y, Pawlik TM, Anders RA, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet. 2013;45:1470-1473.
4. OMIM: #614327. Tumor predisposition syndrome. http://omim.org/entry/614327. Accessed August 23, 2015.
5. Pilarski R, Cebulla CM, Massengill JB, et al. Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome, reporting three new cases. Gene Chromosome Canc. 2014;53:177-182.
6. de la Fouchardière A, Cabaret O, Savin L, et al. Germline BAP1 mutations predispose also to multiple basal cell carcinomas. Clin Genet Clin Genet. 2015;88:273-277.
7. Wadt KA, Aoude LG, Johansson P, et al. A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma. Clin Genet. 2015;88:267-272.
8. Testa JR, Cheung M, Pei J, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2012;43:1022-1025.
9. Wiesener T, Obenaut AC, Murali R, et al. Germline mutations in BAP1 predispose to melanocytic tumours. Nat Genet. 2012;43:1018-1021.
10. Wiesner T, Murali R, Fried I, et al. A distinct subset of atypical spitz tumour is characterized by BRAF mutation and loss of BAP1 expression. Am J Surg Pathol. 2012;36:818-830.
11. Brugarolas J. Molecular genetics of clear-cell renal cell carcinoma. J Clin Oncol. 2014;32:1968-1976.
12. Popova T, Herbert L, Jacquemin V, et al. Germline BAP1 mutations predispose to renal cell carcinomas. Am J Hum Genet. 2013;92:974-980.
13. Abdel-Rahman MH, Pilarski R, Cebulla CM, et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet. 2011;48:856-859.
14. Peña-Llopis S, Vega-Rubín-de-Celis S, Liao A, et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet. 2012;44:751-759.
15. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004;24:115-125.
16. Vauthey JN, Blumgart LH. Recent advances in the management of cholangiocarcinomas. Semin Liver Dis. 1994;14:109-114.
17. Gatto M, Bragazzi MC, Semeraro R, et al. Cholangiocarcinoma: update and future perspectives. Dig Liver Dis. 2010;42:253-260.
18. Khan SA, Thomas HC, Davidson BR, et al. Cholangiocarcinoma. Lancet. 2005;366:1303-1314.
19. Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology risk-factors, and pathogenesis of cholangiocarcinoma. HPB. 2008;10:7-82.
20. Shin HR, Oh JK, Masuyer E, et al. Epidemiology of cholangiocarci-noma: an update focusing on risk factors. Cancer Sci. 2010;101:579-585.
21. Chan-On W, Nairismagi ML, Ong CK, et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet. 2013;45:1474-1478.
22. Betti M, Casalone E, Ferrante D, et al. Inference on germline BAP1 mutations and asbestos exposure from the analysis of familial and sporadic mesothelioma in a high-risk area. Genes Chromosomes Cancer. 2015;54:51-62.
23. Shah AA, Bourne TD, Murali R. BAP1 protein loss by immunohis-tochemistry: a potentially useful tool for prognostic prediction in patients with uveal melanoma. Pathology. 2013;45:651-656.
24. Kalirai H, Dodson A, Faqir S, et al. Lack of BAP1 protein expression in uveal melanoma is associated with increased metastatic risk and has utility in routine prognostic testing. Br J Cancer. 2014;111:1373-1380.
25. Farzin M, Toon CW, Clarkson A, et al. Loss of expression of BAP1 predicts longer survival in mesothelioma. Pathology. 2015;47:302-307.
26. Andrici J, Sheen A, Sioson L, et al. Loss of expression of BAP1 is a useful adjunct which strongly supports the diagnosis of mesothelioma in effusion cytology. Mod Path. 2015;28: 1360-1368.
27. Rusch V, Appelman H, Blackstone E, et al. Cancer Staging Manual. 7th ed. Chicago, IL: American Joint Committee on Cancer, Springer; 2009.
28. Sheffield BS, Hwang HC, Lee AF, et al. BAP1 immunohistochem-istry and p16 FISH to separate benign from malignant mesothelial proliferations. Am J Surg Pathol. 2015;39:977-982.
29. Nasu M, Emi M, Pastorino S, et al. High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol. 2015;10:565-576.
30. Harbour JW, Onken MD, Roberson ED, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330:1410-1413.
31. Haga H, Patel T. Molecular diagnosis of intrahepatic cholangiocarci-noma. J Hepatobiliary Pancreat Sci. 2015;22:114-123.